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Abstract
Background: The human papillomaviruses (HPV) are a large family of non-enveloped DNA viruses, mainly
associated with cervical cancers. Recent epidemiologic evidence has suggested that HPV may be an independent
risk factor for oropharyngeal cancers. Evidence now suggests HPV may modulate the malignancy process in some
tobacco- and alcohol-induced oropharynx tumors, but might also be the primary oncogenic factor for inducing
carcinogenesis among some non-smokers. More evidence, however, is needed regarding oral HPV prevalence
among healthy adults to estimate risk. The goal of this study was to perform an HPV screening of normal healthy
adults to assess oral HPV prevalence.
Methods: Healthy adult patients at a US dental school were selected to participate in this pilot study. DNA was
isolated from saliva samples and screened for high-risk HPV strains HPV16 and HPV18 and further processed using
qPCR for quantification and to confirm analytical sensitivity and specificity.
Results: Chi-square analysis revealed the patient sample was representative of the general clinic population with
respect to gender, race and age (p < 0.05). Four patient samples were found to harbor HPV16 DNA, representing
2.6% of the total (n = 151). Three of the four HPV16-positive samples were from patients under 65 years of age
and all four were female and Hispanic (non-White). No samples tested positive for HPV18.
Conclusions: The successful recruitment and screening of healthy adult patients revealed HPV16, but not HPV18,
was present in a small subset. These results provide new information about oral HPV status, which may help to
contextualize results from other studies that demonstrate oral cancer rates have risen in the US among both
females and minorities and in some geographic areas that are not solely explained by rates of tobacco and alcohol
use. The results of this study may be of significant value to further our understanding of oral health and disease
risk, as well as to help design future studies exploring the role of other factors that influence oral HPV exposure, as
well as the short- and long-term consequences of oral HPV infection.
Background
The human papillomavirus (HPV) has been implicated
as the cause of virtually all cervical cancers worldwide
[1-3]. These represent a large family of non-enveloped
DNA viruses that may be found integrated into the host
genome, non-integrated or episomal, or as a combina-
tion or mixture of these types in infected tissues [4-9].
HPV viruses infect many types of epithelial cells, with
intraepithelial neoplasias accounting for the overwhelm-
ing majority of HPV-related cancers [5,10,11].
Recent epidemiologic evidence has suggested that
HPV may also be an independent risk factor for oro-
pharyngeal cancer, revealing HPV in three times as
many pre-cancerous oral lesions, and almost five times
as many oropharyngeal cancers compared with normal
oral mucosa [12-14]. Of all HPV types, the high-risk
strains HPV16, and to a lesser extent HPV18, are most
commonly identified from oral biopsies [15-21].
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any medium, provided the original work is properly cited.Although the traditional risk factors for developing oro-
pharyngeal cancer remain tobacco use and heavy alcohol
consumption, other risk factors, such as HPV, may play
significant roles in determining whether it develops and
how quickly it may progress [14,19,22-28].
The comparatively low presence of high-risk HPV in
normal tissues and much higher prevalence in pre-can-
cerous and cancerous oropharyngeal lesions may suggest
that HPV preferentially infects already developing oro-
pharyngeal cancers [12-14]. Although it is possible that
the low prevalence in healthy individuals might be attri-
butable to other factors, including improper specimen
collection or assay sensitivit y ,i ti sa l s op o s s i b l et h a t
HPV may function to modulate the malignancy process
in developing or established oropharyngeal tumors, as
has been observed in studies of HPV infection in other
developing cancers [29-39]. For example, recent epide-
miologic and case-control studies have demonstrated
that patients with HPV-positive oropharyngeal tumors
had significantly improved survival rates [12,40,41] and
therapeutic response rates when compared with HPV-
negative controls [42]. Several in vitro studies have
recently investigated possible mechanisms that may
account for these phenotypic changes in oropharyngeal
cancers [25-27]. Evidence is now accumulating that
HPV infection of some oropharyngeal cancers correlates
with increased survival rates and better prognosis
among some patients due to these changes in cellular
responsiveness [40-45]. These studies highlight the need
to understand not only the prevalence of oral HPV
infection, but also the duration and persistence of such
infections, due to their potential to affect oropharyngeal
tumor progression.
It is likely that HPV may modulate the malignancy
process in some tobacco- and alcohol-induced orophar-
yngeal cancers, but may also be the primary oncogenic
factor for inducing carcinogenesis in a subset of patients
without these traditional risk factors. Some evidence has
demonstrated that non-tobacco and non-alcohol related
oropharyngeal cancers were six times more likely to har-
bor HPV infections than case-matched controls [46]. To
accurately evaluate risk, more estimates of oral HPV
prevalence among healthy adults are needed. Interna-
tional studies have evaluated HPV prevalence in healthy
adults using biopsy samples, revealing prevalence rates
that ranged from 0 to 15% [20,47-51]. In addition, other
studies have begun to report less invasive saliva and oral
lavage-based testing methods to identify HPV among
healthy adult saliva samples, revealing prevalence rates
between 2.8 to 25% [15,52-60].
Some of these oral HPV screening studies were per-
formed in the US on normal, healthy adults, in addition
to oropharyngeal cancer patients [57,58,61]. These stu-
dies have reported much lower rates, between 1.3 and
7%, than in previous international studies [47,50,53].
Based upon this information, the goal of this project
was to perform a screening for the most prevalent high-
risk HPV strains, HPV16 and HPV18, in normal healthy
adults. This pilot study was performed in Nevada, a
state recently documented to have increasing rates of
oropharyngeal cancer between 1997 and 2005 - despite
declining rates of tobacco and alcohol use in the state,
as well as declining rates of oropharyngeal cancer
nationally [23,24]. The long-term goal is to provide
more detailed information about high-risk oral HPV
prevalence to allow for more robust estimates of oro-
pharyngeal cancer risk.
Methods
Human Subjects
The protocol for this study titled “T h eP r e v a l e n c eo f
Oral Human Papilloma Virus (HPV) in the University of
Nevada, Las Vegas - School of Dental Medicine (UNLV-
SDM) Clinic Population” w a sf i l e d ,a m e n d e d ,a n d
approved by the UNLV Office of Research Integrity -
Human Subjects (OPRS#1002-3361) on April 9, 2010. In
brief, subjects in this convenience sample were recruited
by members of the UNLV-SDM Clinic during their den-
tal visit on one of 15 clinic dates. Informed Consent was
required and was conducted onsite. Inclusion criteria:
subjects had to be 18 years old or older and must agree
to participate. Exclusion criteria: subjects younger than
18 years of age, subjects that declined to participate, and
subjects with prior diagnosis of oropharyngeal cancer
were excluded.
Sample size
To determine an appropriate sample size, previous stu-
dies that screened for high-risk oral HPV in healthy
adults were evaluated to determine the range of sample
sizes, which varied greatly from 12 - 1,680 [47-62]. Pre-
vious research at UNLV and the UNLV-SDM clinic
demonstrated low participation rates for invasive, blood-
based screenings [63], but higher rates of participation
using non-invasive biomonitoring and screening meth-
ods, including saliva collection (unpublished data).
These studies had sample sizes ranging from 16 - 200.
Based upon this combined information the maximum
sample size was estimated to be 200.
Saliva Collection Protocol
In brief, healthy adults who agreed to participate were
given a small, sterile saliva collection container, a 50 mL
sterile polypropylene tube from Fisher Scientific (Fair
Lawn, NJ). Participants were then asked to chew on a
small piece of paraffin wax for one minute and then to
expectorate. Samples were stored on ice until transport
to a biomedical laboratory for analysis. Each saliva
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number to prevent research bias. Demographic informa-
tion regarding the sample was concurrently collected,
which consisted of age, gender, and ethnicity only.
Cell counting and DNA isolation
All samples were centrifuged for 10 minutes at 2,100 g
(RCF) and the pellet washed with 1X phosphate-buf-
fered saline (PBS) (HyClone: Logan, UT) and resus-
p e n d e di n5m Lo f1 XP B S .C e l ln u m b e rw a s
determined using Trypan Blue (Fisher Scientific: Fair
Lawn, NJ) using a Zeiss Axiovert 40 inverted micro-
scope (Gottingen, Germany) and a hemacytometer
(Fisher Scientific: Fair Lawn, NJ). To determine if any
samples harbored the HPV virus, DNA was isolated
f r o mt h es a l i v as a m p l eu s i n gam i n i m u mo f3 . 5×1 0
5
cells and the GenomicPrep DNA isolation kit (Amer-
sham Biosciences: Buckinghamshire, UK), using the pro-
cedure recommended by the manufacturer, as previously
described [26,27,32]. DNA purity was calculated using
ratio measurements of absorbance at 260 and 280 nm
(A260/A280 ratio between 1.7 and 2.0).
Polymerase chain reaction (PCR)
DNA from each sample was then used to perform PCR
with the Fisher exACTGene complete PCR kit (Fisher
Scientific: Fair Lawn, NJ) and a Mastercycler gradient
thermocycler (Eppendorf: Hamburg, Germany) using the
following primers for HPV16 [26,27], HPV18 [27,32],
and glyceraldehyde- 3- phosphate dehydrogenase
(GAPDH) [64], synthesized by SeqWright (Houston,
TX):
HPV16 forward primer,
ATGTTTCAGGACCCACAGGA;
HPV16 reverse primer,
CCTCACGTCGCAGTAACTGT;
HPV18 forward primer,
ATGGCGCGCTTTGAGGATCC;
HPV18 reverse primer,
GCATGCGGTATACTGTCTCT;
GAPDH forward primer,
ATCTTCCAGGAGCGAGATCC;
GAPDH reverse primer,
ACCACTGACACGTTGGCAGT;
One μg of template DNA was used for each reaction.
The initial denaturation step ran for three minutes at
94°C. A total of 30 amplification cycles were run, con-
sisting of 30 second denaturation at 94°C, 60 seconds of
annealing at 58°C, and 30 seconds of extension at 72°C.
Final extension was run for five minutes at 72°C. The
PCR reaction products were separated by gel electro-
phoresis using Reliant 4% NuSieve
® 3:1 Plus Agarose
gels (Lonza: Rockland, ME). Bands were visualized by
UV illumination of ethidium-bromide-stained gels and
captured using a Kodak Gel Logic 100 Imaging System
and 1D Image Analysis Software (Eastman Kodak:
Rochester, NY).
Quantitative PCR (qPCR)
DNA samples were then processed using qPCR to pro-
vide more specific and sensitive quantification. Primers
and probes were designed using Roche Universal Probe
library (UPL) assay design software to amplify the region
overlapping E6 and E7 gene sequence of HPV16 [Gen-
Bank: K02718] and the human b-actin housekeeping
gene [GenBank: M10277]. All primers were purchased
from Sigma-Aldrich (St. Louis, MO.) and probes pur-
chased from Roche Applied Science (Indianapolis, IN.)
HPV16 E6/E7 forward primer 5’-CAACTGATCTC-
TACTGTTATGAGCAA-3’, HPV16 E6/E7 reverse pri-
mer 5’-CCAGCTGGACCATCTATTTCA-3’, HPV16 E6/
E7 hydrolysis “Taqman” probe 5’-(fam)-AGGAGGAG-
(dark quencher dye)-3’ (UPL probe #63) was used to
amplify the 73 base pair (bp) region between the 535
nucelotide (nt) position and 607 nt position. Human b-
actin forward primer 5’-GTGGGGTCCTGTGGTGTG-
3’,h u m a nb-actin 5’-GAAGGGGACAGGCAGTGA-3’,
human b-actin hydrolysis “Taqman” probe 5’-(fam)-
GGGAGCTG-(dark quencher dye)-3’ (UPL probe #24)
amplified the 61 bp region between 2642 nt position
and 2702 nt position.
The real-time reaction mixture was prepared in a
LightCycler
® 480 multiwell Plate 96 containing 1×
LightCycler
® 480 Probes Master (Roche Applied
Sciences), 1 μM of each respective primer set (forward
and reverse), 0.2 μMo fr e s p e c t i v ep r o b e ,a n d2μlo f
DNA template; in a 20 μl final reaction volume. The
probes master mix contained reaction buffer, dNTP mix
(including dUTP in place of dTTP), 3.2 mM MgCl2, and
Taq DNA polymerase. The real-time PCR assay was
performed on a LightCycler 480 system (Roche Applied
Science) with the following cycle parameters: pre-incu-
bation for initial enzyme activation at 95°C for 10 min-
utes, followed by 45 cycles of 95°C for 10 seconds (ramp
rate 4.4°C/second), 60°C for 30 seconds (ramp rate 2.2°
C/second) and 72°C for 1 second (ramp rate 4.4°C/sec-
ond). Following amplification phase, a cooling step was
performed at 40°C for 30 seconds (ramp rate of 2.2°C/
second). Acquisition of the fluorescence signal was per-
formed using Mono Hydrolysis Probe setting (465-510
nm) following the 72°C extension phase of each cycle.
All samples were carried out in triplicate.
Analytic sensitivity
The CaSki (American Type Culture Collection; Mana-
ssas, VA) cervical adenocarcinoma cell line was used to
develop standard curves for both the HPV16 (600
copies/genome) and b-actin (2 copies/genome) genes.
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fold starting at 50 ng to 0.0005 ng [65]. This step
allowed for relative quantification of the input DNA
level and final quantity as the number of viral copies/
genome/cell. Quantification was achieved using Cycle
Threshold (CT) measured with the second derivative
maximum method (LightCycler 480 Software version
1.5.0.39; Roche Applied Science). Saliva samples > 0.001
copy/genome were considered HPV positive. Specificity
analysis was performed on qPCR assay against HPV18
and found to be 100% specific (data not shown).
Statistical evaluation
Sensitivity and specificity were calculated as the propor-
tion of true positives and true negatives (cutoff value >
0.001 copies/genome), respectively. Following the acqui-
sition of saliva samples and HPV screening results,
demographic information from each sample was com-
pared with the overall demographic profile of the
UNLV-SDM patient pool (N = 71, 051) using a chi-
square (c2) test, to determine if any characteristic (gen-
der, race, age) was different than expected among the
patients evaluated in this study (n = 151). A probability
level of alpha (a) = 0.05 was used to determine statisti-
cal significance.
Results
Samples of saliva were collected from 151 UNLV-SDM
patients between June 2 and October 1, 2010. The
patients from whom samples were collected and
screened were not statistically different from the overall
UNLV-SDM clinic population with respect to gender,
race, or age (Table 1). More specifically, the total num-
ber of females and males in the sample was roughly
equal (52.3% and 47.7%, respectively) and not signifi-
cantly different than the overall clinic population (p =
0.589). There were slightly more White patients in the
study sample (48.3%) than in the overall UNLV-SDM
population (40.8%) (p = 0.133). In addition, there were
slightly fewer 18 - 64 year olds in the sample (80.8%)
than in the overall clinic (85.3%) (p = 0.354).
Analysis of saliva samples revealed cell counts varying
between 0.8 - 2.4 × 10
6 cells/mL (Table 2). DNA was
successfully isolated from all collected saliva samples,
with average DNA concentrations ranging between 820
- 1047 ng/μL. Absorbance measurements and A260/
A280 ratio analysis confirmed the purity of the DNA
isolates, which averaged between 1.87 and 2.05.
The extracted DNA was subsequently screened for the
presence of HPV16 and HPV18 using PCR (Figure 1).
From this screening, four patient samples were deter-
mined to be HPV- positive, which represented 2.6% of
the total screened (n = 4/151). All four samples har-
bored HPV16 DNA and none were found to be positive
for HPV18. Although a positive sample pool of only
four patients does not allow for any broader inferences
or conclusions, a preliminary descriptive analysis of
demographic information revealed these four samples
were from females, who were also minority (non-White,
Hispanic) (Table 3). Three of the four samples were
from patients between 18 - 64 years of age (2.0%), and
one sample came from a patient over 65 years of age
(0.7%).
DNA samples were then processed using quantitative
qPCR to provide quantitative assessment, as well as
measurement of sensitivity and specificity (Figure 2).
Analysis of the range of copy number/genome for the
housekeeping gene (b-actin) within HPV-negative
(range: 4 - 363 copies/genome) and HPV-positive sam-
ples (range: 75-1096) were similar and well above the
cutoff value (> 0.1 copies/genome). Analysis of qPCR
results in copy number/genome for HPV revealed strik-
ing differences in copy numbers between HPV-negative
(range: 0.0001 - 0.000004 copies/genome) and HPV-
positive (range: 70 - 111), which were easily distin-
guished using the cutoff value (> 0.001 copies/genome).
No false positives or false negatives were found, demon-
strating sufficient sensitivity and specificity to ascertain
the proportion of true positives (4/4 or 100%) and true
negatives (147/151 or 100%).
Discussion
The primary aim of this study was to perform an oral
screening of normal healthy adults in Nevada for high-
risk HPV. Previous attempts at this institution and
within the state to obtain blood-based samples for other
types of screenings, such as lead (Pb) levels, have been
largely unsuccessful due to patient apprehension and
fear of blood collection [63]. To avoid these specific
problems, this study utilized non-invasively collected sal-
iva to perform this analysis. These efforts ultimately
allowed for the collection and screening of dozens of
patient samples; a marked improvement in patient parti-
cipation rates over other previous, but similar, attempts
to collect biological specimens from the local
Table 1 Demographic analysis of study participants
Variables UNLV-SDM Study sample Statistical analysis
Gender
Female n = 35,952 (50.6%) n = 79 (52.3%) c2 = 0.119, d.f. = 1
Male n = 35,099 (49.4%) n = 72 (47.7%) p = 0.589
Race
White n = 28,989 (40.8%) n = 73 (48.3%) c2 = 1.621, d.f. = 1
Non-White n = 42,062 (59.2%) n = 78 (51.7%) p = 0.133
Age
18 - 64 years n = 60,598 (85.3%) n = 122 (80.8%) c2 = 1.056, d.f. = 1
65 + n = 10,453 (14.7%) n = 29 (19.2%) p = 0.354
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new data from a previously unscreened patient popula-
tion and geographic area to complement the growing
corpus of information about oral HPV prevalence
among healthy adults.
These data demonstrated a prevalence rate of high-
risk oral HPV (2.6%) virtually the same as the most
recent multinational studies of healthy, cancer-free
adults (3.1% to 5%) [61,62]. Over the past few decades,
international studies have evaluated HPV prevalence in
healthy adults using biopsy samples, which reported
widely variable prevalence rates that ranged from 0 -
15% [47-51]. However, other recently published reports
screening for oral HPV infection among healthy adults
using saliva and oral lavage testing reported overall pre-
valence rates that were also close to this range (1.3%,
2.8%, 7%) [52-59].
In addition, although the results of this study found
oral HPV infection only among four patients, who were
minority and female, the vast majority of female and
minority patients in this study had no evidence of oral
HPV infection. As an initial pilot study, these data sug-
gest a more comprehensive and in-depth analysis of this
population may be necessary, as recent epidemiologic
studies have shown that rates of oropharyngeal cancer
haven risen sharply among minority females in the US,
despite overall declining rates [66]. More generally, rates
of oropharyngeal cancer have risen among some minor-
ity subgroups [67], despite an overall decline among the
general population in the US [23,24,68]. This may be
explained, in part, by higher rates of tobacco and
alcohol use, but may also be attributable to other factors
including education, income, stress, diet, health literacy
and exposure to oral infectious agents [22,25]. This pilot
study provides preliminary information about oral HPV
prevalence and the results suggest that further investiga-
tion may be warranted, particularly in light of the health
disparities facing both females and minorities in Nevada
and the US, in general [23,24].
This study also revealed the presence of the high-risk
strain HPV16, but not HPV18. Although some reports
have suggested that oral HPV infection may involve
multiple HPV strains [15-21,69], this result is not dis-
similar from other findings which suggest HPV16 may
account for the overwhelming majority of HPV-positive
oral samples [48,49,53,57,59]. It is likely that further
expansion of this project to include larger samples will
uncover additional HPV strains to provide more exten-
sive estimates of oral HPV infection within this
population.
This study had several limitations that should be con-
sidered. First, although the non-invasive nature of this
study was sufficient for the recruitment and screening of
a significant number of patients, the overall sample size
was somewhat limited in comparison to the larger mul-
tinational studies previously mentioned [57,58,61]. The
number of healthy adults screened for oral HPV in this
pilot study, however, compares favorably with a number
of other reports - with sample sizes ranging from 12 to
97 [20,47-53]. Second, detailed demographic and beha-
vioral data were not designated as critical to the initial
goals of this pilot study, however, the inclusion of smok-
ing and tobacco use, as well as more detailed informa-
tion about other behaviors, housing, education, income
and other socioeconomic indicators, as well as sexual
Table 2 Cell count and DNA isolation
Cell count (cells/mL) Average DNA concentration (ng/μL) A260/A280 Samples (n)
0.8 - 1.2 × 10
6 915 2.05 31
1.6- 1.9 × 10
6 820 1.87 94
2.1 - 2.4 × 10
6 1047 1.95 26
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Figure 1 Screening of patient samples for HPV. PCR using DNA
extracted from patient samples (n = 151) was screened using
HPV16- and HPV18-specific primers, which revealed four samples
harbored HPV16 (2819, 2718, 2527, and 2430). No samples were
found to harbor HPV18. DNA extracted previously from cervical
adenocarcinoma cell lines, CaSki and GH354, was used as HPV16
and HPV18 positive controls, respectively.
Table 3 Analysis of HPVscreening
Variables HPV16-positive HPV18-positive HPV-negative
Gender
Female n = 4 (2.6%) n = 0 n = 75 (49.7%)
Male n = 0 n = 0 n = 72 (47.7%)
Race
White n = 0 n = 0 n = 73 (48.3%)
Non-White n = 4 (2.6%) n = 0 n = 74 (49.0%)
Age
18 - 64 years n = 3 (2.0%) n = 0 n = 119 (78.8%)
65 + n = 1 (0.7%) n = 0 n = 28 (18.5%)
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tigations [55,58,59,70]. Finally, screening for additional
high-risk HPV strains [71-75] and other oral infectious
a g e n t sm a yb ep o s s i b l ei nf u t u r es t u d i e sw i t hm o r es i g -
nificant resources and personnel.
Conclusions
This study successfully recruited patients and screened
saliva samples for high-risk HPV, confirming HPV16,
but not HPV18, was present in a small subset of the
healthy adult patients in a US dental school clinic popu-
lation. These patients were female and minority. Many
health disparities face females and minorities in the US,
a n dw i t hs o m ee v i d e n c es u g g e s t i n gt h a ts m o k i n ga n d
oropharyngeal cancer rates may be increasing in these
population subgroups, the results of this study may be
of significant value to other dental, medical, and health
care professionals to further an understanding of oral
health and disease risk.
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(copies/genome)     (copies/genome)    (copies/genome)
HPV-positive
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1096                            87                            0.00039                                        2819
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HPV-negative
Range: Range: Range:
4 – 363                       0.0001 - .000015 0.001 – 0.000004 n = 147
Figure 2 Graphic analysis of qPCR HPV screening results. Plotting of copy number/genome for housekeeping gene (b-actin) was similar
from samples of HPV-positive (range: 75-1096) and HPV-negative samples (range: 4 - 363 copies/genome). Copy number/genome using qPCR
was significantly above the cutoff value (> 0.1 copies/genome), confirming the HPV-positive samples did harbor HPV16 DNA (range: 70 - 111
copies/genome), but not HPV18. Values for HPV-negative samples were well beneath the cutoff value (range: 0.0003 - 0.000004 copies/genome),
with the exception of three samples (2867, 2854, 2792) that were beneath the limit of detection.
Turner et al. BMC Oral Health 2011, 11:28
http://www.biomedcentral.com/1472-6831/11/28
Page 6 of 8Author details
1University of Nevada, Las Vegas - School of Community Health Sciences,
Department of Environmental and Occupational Health, Las Vegas, Nevada,
USA.
2University of Nevada, Reno - School of Medicine, Department of
Surgery, Las Vegas, Nevada, USA.
3University of Nevada, Las Vegas - School
of Dental Medicine, Department of Biomedical Sciences, Las Vegas, Nevada,
USA.
Authors’ contributions
KK, SW, AB and RW conceived, monitored, and coordinated the
experimental design. RB, JC, JF, DM, and JM were responsible for recruiting
patients, informed consent, collecting samples, and some biomedical
analysis. DT, KK, and SW carried out the DNA extractions, PCR, and qPCR
analysis. KK, SW and DT were responsible for the data analysis, as well as the
writing and editing of this manuscript. All authors have read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 30 December 2010 Accepted: 10 October 2011
Published: 10 October 2011
References
1. Zhou W, Tyring SK, Brysk M, Chan T: Immortalization of differentiated
human keratinocytes by human papillomavirus (HPV) 16 DNA. Journal of
Dermatological Science 1996, 13:140-152.
2. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV,
Snijders PJF, Peto J, Meijer CJLM, Munoz N: Human papillomavirus is a
necessary cause of invasive cervical cancer worldwide. J Pathol 1999,
189:12-19.
3. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human
papillomavirus types in invasive cervical cancer worldwide: a meta-
analysis. Br J Cancer 2003, 88:63-73.
4. Das BC, Sharma JK, Gopalakrishna V, Luthra UK: Analysis by polymerase
chain reaction of the physical state of human papillomavirus type 16
DNA in cervical preneoplastic and neoplastic lesions. J Gen Virol 1992,
73(Pt 9):2327-36.
5. zur Hausen H: Papillomaviruses in human cancers. Proc Assoc Am
Physicians 1999, 111(6):581-7, Review.
6. Kalantari M, Blennow E, Hagmar B, Johansson B: Physical state of HPV16
and chromosomal mapping of the integrated form in cervical
carcinomas. Diagn Mol Pathol 2001, 10(1):46-54.
7. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical
application. Nat Rev Cancer 2002, 2(5):342-50.
8. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H:
Classification of papillomaviruses. Virology 2004, 324(1):17-27, Review.
9. Ramanakumar AV, Goncalves O, Richardson H, Tellier P, Ferenczy A,
Coutlee F, Franco EL: Human papillomavirus (HPV) types 16, 18, 31, 45
DNA loads and HPV-16 integration in persistent and transient infections
in young women. BMC Infect Dis 2010, 10(1):326.
10. McCance DJ: Human papillomaviruses and cancer. Biochim Biophys Acta
1986, 823:195-205.
11. McCance DJ, Kopan R, Fuchs E, Laimins LA: Human papillomavirus type 16
alters human epithelial cell differentiation in vitro. Proc Natl Acad Sci USA
1988, 85:7169-7173.
12. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L,
Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D:
Evidence for a causal association between human papillomavirus and a
subset of head and neck cancers. J Natl Cancer Inst 2000, 92:675-677.
13. Miller CS, Johnstone BM: Human papillomavirus as a risk factor for oral
squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med
Oral Pathol 2001, 91:622-635.
14. van Houten VM, Snijders PJ, van den Brekel MW, Kummer JA, Meijer CJ, van
Leeuwen B, Denkers F, Smeele LE, Snow GB, Brakenhoff RH: Biological
evidence that human papillomaviruses are etiologically involved in a
subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001,
93:232-235.
15. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P,
Rajkumar T, Sridhar H, Rose B, Pintos J, Fernandez L, Idris A, Jose
Sanchez M, Nieto A, Talamini R, Tavani A, Bosch FX, Reidel U, Snijders PJF,
Meijer CJLM, Viscidi R, Munoz N, Franceschi S: Human papillomavirus and
oral cancer: The International Agency for Research on Cancer
multicenter study. J Natl Cancer I 2003, 95:1772-1783.
16. Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human papillomavirus
types in head and neck squamous cell carcinomas worldwide: a
systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14:467-475.
17. Syrjanen S: Human papillomavirus (HPV) in head and neck cancer. J Clin
Virol 2005, 32:s59-66.
18. Gillison ML, Shah KV: Chapter 9: Role of mucosal human papillomavirus
in nongenital cancers. J Natl Cancer Inst Monogr 2003, 31:57-65.
19. Goon PK, Stanley MA, Ebmeyer J, Steinsträsser L, Upile T, Jerjes W, Bernal-
Sprekelsen M, Görner M, Sudhoff HH: HPV & head and neck cancer: a
descriptive update. Head Neck Oncol 2009, 1:36.
20. Ostwald C, Müller P, Barten M, Rutsatz K, Sonnenburg M, Milde-Langosch K,
Löning T: Human papillomavirus DNA in oral squamous cell carcinomas
and normal mucosa. J Oral Pathol Med 1994, 23(5):220-5.
21. Ostwald C, Rutsatz K, Schweder J, Schmidt W, Gundlach K, Barten M:
Human papillomavirus 6/11, 16 and 18 in oral carcinomas and benign
oral lesions. Med Microbiol Immunol 2003, 192(3):145-8, Epub 2002 Nov 1.
22. Shiboski CH, Schmidt BL, Jordan RC: Tongue and tonsil carcinoma:
increasing trends in the U.S. population ages 20-44 years. Cancer 2005,
103(9):1843-9.
23. Kingsley K, O’Malley S, Chino M: Analysis of oral cancer epidemiology in
the US reveals state-specific trends: implications for oral cancer
prevention. BMC Public Health 2008, 8(1):87.
24. Bunnell A, Pettit N, Reddout N, Sharma K, O’Malley S, Chino M, Kingsley K:
Analysis of primary risk factors for oral cancer from select US states with
increasing rates. Tobacco Induced Diseases 2010, 8:5.
25. Feller L, Khammissa RA, Wood NH, Lemmer J: Epithelial maturation and
molecular biology of oral HPV. Infect Agent Cancer 2009, 4:16.
26. Kingsley K, Johnson D, O’Malley S: Transfection of oral squamous cell
carcinoma with human papillomavirus-16 induces proliferative and
morphological changes independent of cellular adhesion in vitro. Cancer
Cell International 2006, 6:14.
27. Reddout N, Christensen T, Bunnell A, Jensen D, Johnson D, O’Malley S,
Kingsley K: High risk HPV types 18 and 16 are potent modulators of oral
squamous cell carcinoma phenotypes in vitro. Infectious Agents and
Cancer 2007, 2(1):21.
28. Jung AC, Briolat J, Millon R, de Reynies A, Rickman D, Thomas E,
Abecassis J, Clavel C, Wasylyk B: Biological and clinical relevance of
transcriptionnally active human papillomavirus (HPV) infection in
oropharynx squamous cell carcinoma. Int J Cancer 2009.
29. Williams GR, Talbot IC: Anal carcinoma–a histological review.
Histopathology 1994, 25(6):507-16.
30. Proby CM, Harwood CA: Role of human papillomaviruses in warts and
cancer..
31. Amarante MK, Watanabe MA: The possible involvement of virus in breast
cancer. J Cancer Res Clin Oncol 2009, 135(3):329-37, Epub 2008 Nov 14.
32. Kingsley K, Zuckerman J, Davis M, Matteucci M, Knavel A, Rinehart J, Tran V,
Woyciehowsky D, Jenkins P, Yu Rui, Nguyen DH, O’Malley S: Induction of
Differential Growth in vitro by High-risk Human Papillomavirus in
Human Breast Cancer Cell Lines is Associated with Caspase
Dysregulation. Journal of Cancer Science and Therapy 2009, 1(2):62-71.
33. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S:
Human papillomavirus prevalence and type distribution in penile
carcinoma. J Clin Pathol 2009, 62(10):870-8, Epub 2009 Aug 25.
34. Rezazadeh A, Laber DA, Ghim SJ, Jenson AB, Kloecker G: The role of
human papilloma virus in lung cancer: a review of the evidence. Am J
Med Sci 2009, 338(1):64-7.
35. Shukla S, Bharti AC, Mahata S, Hussain S, Kumar R, Hedau S, Das BC:
Infection of human papillomaviruses in cancers of different human
organ sites. Indian J Med Res 2009, 130(3):222-33.
36. Pow-Sang MR, Ferreira U, Pow-Sang JM, Nardi AC, Destefano V:
Epidemiology and natural history of penile cancer. Urology 2010, 76(2
Suppl 1):S2-6.
37. Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ: Changing patterns of tonsillar
squamous cell carcinoma in the United States. Cancer Causes Control
2000, 11(6):489-95.
38. Kan C-Y, Iacopetta BJ, Lawson JS, Whitaker NF: Identification of human
papillomavirus DNA sequences in human breast cancer. British Journal of
Cancer 2005, 93:946-948.
Turner et al. BMC Oral Health 2011, 11:28
http://www.biomedcentral.com/1472-6831/11/28
Page 7 of 839. Khan NA, Castillo A, Koriyama C, Kijima Y, Umekita Y, Ohi Y, Higashi M,
Sagara Y, Yoshinaka H, Tsuji T, Natsugoe S, Douchi T, Eizuru Y, Akiba S:
Human papillomavirus detected in female breast carcinomas in Japan.
Br J Cancer 2008, 99(3):408-414.
40. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM: Human
papillomavirus infection and survival in oral squamous cell cancer: a
population-based study. Otolaryngol Head Neck Surg 2001, 125(1):1-9.
41. Badaracco G, Rizzo C, Mafera B, Pichi B, Giannarelli D, Rahimi SS, Vigili MG,
Venuti A: Molecular analyses and prognostic relevance of HPV in head
and neck tumours. Oncol Rep 2007, 17(4):931-9.
42. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A,
Gillison ML: Improved survival of patients with human papillomavirus-
positive head and neck squamous cell carcinoma in a prospective
clinical trial. J Natl Cancer Inst 2008, 100(4):261-9, Epub 2008 Feb 12.
43. Klozar J, Kratochvil V, Salakova M, Smahelova J, Vesela E, Hamsikova E,
Betka J, Tachezy R: HPV status and regional metastasis in the prognosis
of oral and oropharyngeal cancer. Eur Arch Otorhinolaryngol 2008,
265(Suppl 1):S75-82, Epub 2007 Dec 20.
44. Zhao D, Xu QG, Chen XM, Fan MW: Human papillomavirus as an
independent predictor in oral squamous cell cancer. Int J Oral Sci 2009,
1(3):119-25.
45. Mehta V, Yu GP, Schantz SP: Population-based analysis of oral and
oropharyngeal carcinoma: Changing trends of histopathologic
differentiation, survival and patient demographics. Laryngoscope 2010,
120(11):2203-12.
46. Andrews E, Seaman WT, Webster-Cyriaque J: Oropharyngeal carcinoma in
non-smokers and non-drinkers: a role for HPV. Oral Oncol 2009,
45(6):486-91, Epub 2008 Nov 21.
47. Mao EJ: Prevalence of human papillomavirus 16 and nucleolar organizer
region counts in oral exfoliated cells from normal and malignant
epithelia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995,
80(3):320-9.
48. Cruz IB, Snijders PJ, Steenbergen RD, Meijer CJ, Snow GB, Walboomers JM,
van der Waal I: Age-dependence of human papillomavirus DNA presence
in oral squamous cell carcinomas. Eur J Cancer B Oral Oncol 1996,
32B(1):55-62.
49. Bouda M, Gorgoulis VG, Kastrinakis NG, Giannoudis A, Tsoli E, Danassi-
Afentaki D, Foukas P, Kyroudi A, Laskaris G, Herrington CS, Kittas C: “High
risk” HPV types are frequently detected in potentially malignant and
malignant oral lesions, but not in normal oral mucosa. Mod Pathol 2000,
13(6):644-53.
50. do Sacramento PR, Babeto E, Colombo J, Cabral Ruback MJ, Bonilha JL,
Fernandes AM, Pereira Sobrinho JS, de Souza FP, Villa LL, Rahal P: The
prevalence of human papillomavirus in the oropharynx in healthy
individuals in a Brazilian population. J Med Virol 2006, 78(5):614-8.
51. González JV, Gutiérrez RA, Keszler A, Colacino Mdel C, Alonio LV, Teyssie AR,
Picconi MA: Human papillomavirus in oral lesions. Medicina (B Aires) 2007,
67(4):363-8.
52. Gonçalves AK, Giraldo P, Barros-Mazon S, Gondo ML, Amaral RL, Jacyntho C:
Secretory immunoglobulin A in saliva of women with oral and genital
HPV infection. Eur J Obstet Gynecol Reprod Biol 2006, 124(2):227-31, Epub
2005 Sep 6.
53. SahebJamee M, Boorghani M, Ghaffari SR, AtarbashiMoghadam F,
Keyhani A: Human papillomavirus in saliva of patients with oral
squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2009, 14(10):
e525-8.
54. Seaman WT, Andrews E, Couch M, Kojic EM, Cu-Uvin S, Palefsky J, Deal AM,
Webster-Cyriaque J: Detection and quantitation of HPV in genital and
oral tissues and fluids by real time PCR. Virol J 2010, 7:194.
55. Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D,
Haugen TH, Turek LP: Age, sexual behavior and human papillomavirus
infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004,
108(5):766-72.
56. Koppikar P, deVilliers EM, Mulherkar R: Identification of human
papillomaviruses in tumors of the oral cavity in an Indian community.
Int J Cancer 2005, 113(6):946-50.
57. Zhao M, Rosenbaum E, Carvalho AL, Koch W, Jiang W, Sidransky D,
Califano J: Feasibility of quantitative PCR-based saliva rinse screening of
HPV for head and neck cancer. Int J Cancer 2005, 117(4):605-10.
58. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH,
Gillison ML: Case-control study of human papillomavirus and
oropharyngeal cancer. N Engl J Med 2007, 356(19):1944-56.
59. Tachezy R, Klozar J, Rubenstein L, Smith E, Saláková M, Smahelová J,
Ludvíková V, Rotnáglová E, Kodet R, Hamsíková E: Demographic and risk
factors in patients with head and neck tumors. J Med Virol 2009,
81(5):878-87.
60. Fakhry C, D’souza G, Sugar E, Weber K, Goshu E, Minkoff H, Wright R,
Seaberg E, Gillison M: Relationship between prevalent oral and cervical
human papillomavirus infections in human immunodeficiency virus-
positive and -negative women. J Clin Microbiol 2006, 44(12):4479-85, Epub
2006 Oct 4.
61. Kreimer AR, Villa A, Nyitray A, Abrahamsen ME, Papenfuss MR, Smith D,
Hildesheim A, Villa LL, Lazcano-Ponce E, Giuliano AR: The epidemiology of
oral HPV infection among a multinational sample of healthy men. Cancer
Epidemiol Biomarkers Prev 2011, 20(1):172-82.
62. Kreimer AR, Bhatia RK, Messeguer AL, González P, Herrero R, Giuliano AR:
Oral human papillomavirus in healthy individuals: a systematic review of
the literature. Sex Transm Dis 2010, 37(6):386-91.
63. Rothweiler AM, Cabb EE, Gerstenberger SL: The status of childhood lead
poisoning and prevention in Nevada, USA. ScientificWorldJournal 2007,
7:479-92.
64. Wolter F, Turchanowa L, Stein J: Resveratrol-induced modification of
polyamine metabolism is accompanied by induction of c-Fos.
Carcinogenesis 2003, 24(3):469-74.
65. Chuang AY, Chuang TC, Chang S, Zhou S, Begum S, Westra WH, Ha PK,
Koch WM, Califano JA: Presence of HPV DNA in convalescent salivary
rinses is an adverse prognostic marker in head and neck squamous cell
carcinoma. Oral Oncol 2008, 44(10):915-9, Epub 2008 Mar 7.
66. Swango PA: Cancers of the oral cavity and pharynx in the United States:
an epidemiologic overview. J Public Health Dent 1996, 56:309-318.
67. Shiboski CH, Shiboski SC, Silverman S Jr: Trends in oral cancer rates in the
United States, 1973-1996. Community Dent Oral Epidemiol 2000,
28:249-256.
68. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yanick R,
Wingo PA, Jemal A, Feigal EG: Annual report to the nation on the status
of cancer, 1973-1999, featuring implications of age and aging on U.S.
cancer burden. Cancer 2002, 94:2766-2792.
69. Klozar J, Tachezy R, Rotnáglová E, Koslabová E, Saláková M, Hamsíková E:
Human papillomavirus in head and neck tumors: epidemiological,
molecular and clinical aspects. Wien Med Wochenschr 2010, 160(11-
12):305-9.
70. D’Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML: Oral sexual
behaviors associated with prevalent oral human papillomavirus
infection. J Infect Dis 2009, 199(9):1263-9.
71. Rivero ER, Nunes FD: HPV in oral squamous cell carcinomas of a Brazilian
population: amplification by PCR. Braz Oral Res 2006, 20(1):21-4, Epub
2006 May 22.
72. Koyama K, Uobe K, Tanaka A: Highly sensitive detection of HPV-DNA in
paraffin sections of human oral carcinomas. J Oral Pathol Med 2007,
36(1):18-24.
73. Jiang Q, Zhang ZY: The study of HPV prevalence in normal oral mucosa
and oral squamous cell carcinoma. Shanghai Kou Qiang Yi Xue 2007,
16(5):538-41.
74. Kirnbauer R, Schellenbacher C, Shafti-Keramat S, Handisurya A: HPV
infections of the oral and genital mucosa. Possibilities for primary
prevention. Hautarzt 2009, 60(11):878-80.
75. Montaldo C, Mastinu A, Quartuccio M, Piras V, Denotti G, Pisano E, Orrù G:
Detection and genotyping of human papillomavirus DNA in samples
from healthy Sardinian patients: a preliminary study. J Oral Pathol Med
2007, 36(8):482-7.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6831/11/28/prepub
doi:10.1186/1472-6831-11-28
Cite this article as: Turner et al.: High-risk human papillomavirus (HPV)
screening and detection in healthy patient saliva samples: a pilot study.
BMC Oral Health 2011 11:28.
Turner et al. BMC Oral Health 2011, 11:28
http://www.biomedcentral.com/1472-6831/11/28
Page 8 of 8